Mode
Home
Conditions Medications Drug Pipeline Weekly Digests
Text Size
Log in / Sign up
Home › Medications › anti-PD-1

anti-PD-1

2 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
High tumour mutation burden improves overall survival in solid tumours treated with immune checkpoint inhibitors
Oncology Meta-analysis
High tumour mutation burden improves overall survival in solid tumours treated with immune checkpoint inhibitors High Mutation Counts May Predict Better Cancer Survival Outcomes
This systematic review and meta-analysis evaluated 5278 patients with solid tumours treated with immune checkpoint inhibitors or chemotherap…
High mutation counts in tumors may help predict who will survive longer when taking powerful immune-boosting cancer drugs
May 1, 2026
Anti-PD-1 plus chemoradiotherapy improved event-free survival in MS1 subtype nasopharyngeal carcinoma patients compared with chemoradiotherapy alone.
Oncology RCT
Anti-PD-1 plus chemoradiotherapy improved event-free survival in MS1 subtype nasopharyngeal carcinoma patients compared with chemoradiotherapy alone. New Test Picks Who Wins From Cancer Drug
This review analyzed pooled data from two Phase III randomized clinical trials involving 407 patients with locoregionally advanced nasophary…
A new test identifies which nasopharyngeal cancer patients will survive longer when adding immunotherapy to standard radiation and chemother…
Apr 13, 2026